News and Press Releases
Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
6 October 2025 -- London, UK -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements...
Category: Logistics, Other, Pharmaceutical
Posted: October 6, 2025
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency
6 October 2025 -- London, UK and Reykjavik, Iceland -- Advanz Pharma Holdco Limited, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: October 6, 2025
Capital House, 1st Floor, 85 King William Street, London EC4N 7BL
Santhera Announces Approval in Canada for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved therapy for DMD...
Category: Other, Pharmaceutical
Posted: October 3, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE (Aflibercept-mrbb) Pending litigation at the U.S. District Court for the Northern District of West Virginia...
Category: Logistics, Other, Pharmaceutical
Posted: October 2, 2025
SeaBeLife secures €2 million
This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 -- Roscoff, France -- SeaBeLife, a biotechnology company developing...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso, Denosumab Biosimilars
1 October 2025 -- Bengaluru, India and New Jersey, US -- Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced a settlement and...
Category: Logistics, Other, Pharmaceutical
Posted: October 1, 2025
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application forleniolisib in children with APDS aged 4 to 11 years
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based on positive data from...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Five Leading Life Science Organisations Collaborate on Inaugural London Bio-Innovation Week
ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and SLAS will provide delegates with the opportunity for cross-event partnering during London Bio-Innovation week, which runs 1st-5th December, 2025 One...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health
1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Rezon Bio launches as a European biologics CDMO combining cost efficiency and digital innovation.
New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization 29 September 2025 -- Gdańsk, Poland -- Rezon...
Category: BioManufacturing, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 29, 2025
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
A new pooled analysis of the FIBRONEER-IPF and FIBRONEER-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without...
Category: Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: September 29, 2025
Leqembi (lecanemab) long-term 36-month open-label extension data from post-hoc sub-group analysis of ApoE ε4 non-carriers and heterozygotes presented at Alzheimer’s disease congress in Switzerland
Clarity AD open-label extension data show three years of continuous lecanemab treatment in apolipoprotein E ε4 (ApoE ε4) non-carrier and heterozygote patients continued to accrue benefit relative to the Alzheimer's...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 29, 2025
Clinigen to Acquire SSI Strategy, Charting a Seamless Path from Clinical Strategy to Global Commercialisation for Biotech Innovators
29 September 2025 -- London, UK -- Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle, today announced it has entered into a definitive agreement to...
Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: September 29, 2025
Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions
Successfully completed the TRECOS Phase III study, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform Aiming to become the first pharmaceutical company to transition...
Category: Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: September 26, 2025
Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor. 25 September 2025 -- Amsterdam, The Netherlands and Seongnam-Si, Korea -- Synaffix B.V.,...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: September 25, 2025
Pivot Park, Curie Building Kloosterstraat 9 5349 AB Oss The Netherlands
